[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634654":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":15,"responsibleParty":42,"collaborators":44,"id":50,"slug":10,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":18,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Société Algérienne de Formation et Recherche en Oncologie","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Cohort 1",null,"Patients treated with a pertuzumab biosimilar in the neoadjuvant setting for HER2-positive breast cancer.",{"label":13,"type":10,"description":14,"interventionNames":10},"Cohort 2","Patients treated with a pertuzumab biosimilar as first-line therapy in the metastatic setting for HER2-positive metastatic breast cancer.",[16,33],{"facility":17,"status":18,"city":19,"state":10,"zip":10,"country":20,"cosmosGeoPoint":21,"geoPoint":26,"contacts":27},"CAC BLIDA, Algiers, Algeria 16000","RECRUITING","Algiers","Algeria",{"type":22,"coordinates":23},"Point",[24,25],3.08746,36.73225,{"lat":25,"lon":24},[28],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"BOUNEDJAR Adda, Professor","CONTACT","+213 25 20 90 72","contact@esclinicalresearch.com",{"facility":34,"status":18,"city":19,"state":10,"zip":10,"country":20,"cosmosGeoPoint":35,"geoPoint":37,"contacts":38},"CHU Béni Messous, Algiers, Algeria 16000",{"type":22,"coordinates":36},[24,25],{"lat":25,"lon":24},[39],{"name":40,"role":30,"phone":41,"phoneExt":10,"email":32},"Oukkal Mohammed, Professor","+213 219 311 90",{"type":43,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[45,48],{"name":46,"class":47},"ES Clinical Research","UNKNOWN",{"name":49,"class":47},"AlgenPharm","100634654",false,"NCT07542496","Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease","PERTUREAL","Inclusion Criteria:\n\n* Age ≥ 19 years at the time of inclusion;\n* Histologically confirmed diagnosis of HER2-positive invasive breast cancer (IHC 3+ score or HER2 amplification by FISH\u002FCISH\u002FSISH);\n* Decision to initiate treatment with a pertuzumab biosimilar in the neoadjuvant setting (neoadjuvant cohort) or as first-line therapy in the metastatic setting (metastatic cohort), in accordance with local indications;\n* Treatment prescribed as part of routine clinical care (outside of a clinical trial);\n* Patient informed and having provided written informed consent.\n\nExclusion Criteria:\n\n* Treatment with pertuzumab in a therapeutic setting other than neoadjuvant or first-line metastatic (e.g., adjuvant, late recurrence beyond first-line, maintenance therapy alone, etc.);\n* Treatment administered as part of an interventional clinical trial;\n* History of severe allergy or known contraindication to pertuzumab;\n* Medical records unavailable or inability to ensure at least 6 months of minimal follow-up.","FEMALE","19 Years",{"count":59,"type":60},1000,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to describe the real-world utilization patterns of a pertuzumab biosimilar and to evaluate its clinical outcomes in patients with breast cancer in both neoadjuvant and metastatic settings. It also aims to assess pathological complete response (pCR), disease-free survival (DFS) in the neoadjuvant cohort, progression-free survival (PFS) in the metastatic cohort, overall survival (OS), treatment response, and safety and tolerability (adverse events according to CTCAE) across both cohorts.",[64,65],"Breast Cancer","Her 2 Positive Breast Cancer",[67,68,20,69,70,64,71,72,73,74,75,76,77,78,79],"Algerian Study","Real-world data","Biosimilar","Pertuzumab","Cancer","Breast cancer in Algerian patients","HER2-Positive Breast Cancer","Neoadjuvant Therapy","Anti-HER2 Therapy","Cohort Study","Non-Interventional Study","HER2-Targeted Therapy","Observational Study","2026-04-14",{"date":82,"type":83},"2026-04-21","ACTUAL",{"date":85,"type":83},"2026-01-15",{"date":87,"type":60},"2027-01-15",{"name":5,"class":6},2]